Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2023.2296561 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Katrina S Firlik und 5 weiteren Autor:innen. Beteiligte Einrichtung: HealthPrize Technologies, Norwalk, CT, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Tiotropium Bromide, Bronchodilator Agents, Drug Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, HealthPrize Technologies.
Themen: COPD
Abstract (Originalsprache)
OBJECTIVE: To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD). METHODS: In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs. RESULTS: Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs. CONCLUSIONS: Program participants showed improved COPD medication adherence and persistence compared to nonparticipants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HealthPrize Technologies, Norwalk, CT, USA.
- IQVIA, Health Economics and Outcomes Research, Falls Church, VA, USA.
- Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Förderung
- Boehringer Ingelheim
- HealthPrize Technologies
Zitieren
APA
Firlik, K. S., Anupindi, V. R., Hayes, V., DeKoven, M., Shaikh, A., & Franchino-Elder, J. (2024). Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2296561
Vancouver
Firlik KS, Anupindi VR, Hayes V, DeKoven M, Shaikh A, Franchino-Elder J. Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2296561
BibTeX
@article{Firlik2024,
author = {Firlik, Katrina S and Anupindi, Vamshi Ruthwik and Hayes, Vincent and DeKoven, Mitchell and Shaikh, Asif and Franchino-Elder, Jessica},
title = {Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2023.2296561}
}
EUVIMED